Skip to content

Uterus Transplantation LD - Feasibility Study - Sahlgrenska - BMC

Uterus Transplantation LD - Feasibility Study - Sahlgrenska - Bellevue Medical Centre

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03590405
Acronym
GOT-BMC-UTx
Enrollment
2
Registered
2018-07-18
Start date
2018-06-15
Completion date
2021-12-01
Last updated
2021-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female, Mrk Anomaly

Keywords

uterus, infertility, transplantation

Brief summary

Medical know-how concerning uterus transplantation will be transferred to new site by structured process involving theory, animal workshops and a clinical feasibility study on human subjects.

Detailed description

Medical know-how concerning uterus transplantation will be transferred to new site by structured process involving theory, animal workshops and surgery. Theory and common animal workshops have been ongoing for 3 years. The team from Bellevue Medical Centre is affiliated to St Joseph, University, Beirut

Interventions

PROCEDUREuterus transplantation surgery and IVF

IVF before surgery living donor uterus transplantation ET

Sponsors

Saint Joseph University, at Bellevue Medical Centre
CollaboratorUNKNOWN
Sahlgrenska University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

recipient * age \< 38 years * psychologicaly stable * BMI \< 35 * no systemic disease * no standing medication * in a stable relationship or married * normal ovarian reserve * absolute uterine factor infertility * normal kidney function Inclusion criteria donor * close relative to recipient * age \< 60 years * normal pregnancies * maximum two cesarean sections * BMI \< 35 * no major systemic disease * no previous major surgery

Design outcomes

Primary

MeasureTime frameDescription
live birth3 yearslive birth

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026